Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

People who can't afford the name-brand drugs have been flocking to compounded versions, which are available at a fraction of ...

Adding an anti-obesity medication just one month after behavioral therapy begins-rather than waiting the currently recommended six months-can more than double weight loss for patients who struggle ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

Adding an anti-obesity medication just one month after behavioral therapy begins—rather than waiting the currently ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Taylor McDaniels started taking medication to help her lose weight, but it's led to changes to many of her habits, including ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity medications compared to lifestyle modification alone. Results indicate that ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

As FDA shortages lift, patients and physicians explore new options for continued treatment with compounded GLP-1 medications.

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...